ETC
IPHA

Exchange Traded Concepts’s Innate Pharma IPHA Stock Holding History

Exchange Traded Concepts’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-62,752
Closed -$112K – 1463
2025
Q1 		$112K Sell
62,752
-14,598
-19% -$28.5K ﹤0.01% 1120
2024
Q4 		$143K Hold
77,350
– – ﹤0.01% 1069
2024
Q3 		$177K Sell
77,350
-8,887
-10% -$19.6K ﹤0.01% 1000
2024
Q2 		$167K Sell
86,237
-26,833
-24% -$67.4K ﹤0.01% 894
2024
Q1 		$326K Buy
113,070
+66,182
+141% +$173K 0.01% 773
2023
Q4 		$131K Buy
46,888
+11,890
+34% +$29.5K ﹤0.01% 850
2023
Q3 		$88.5K Sell
34,998
-7,433
-18% -$21.8K ﹤0.01% 945
2023
Q2 		$133K Buy
+42,431
New +$130K ﹤0.01% 879

Other funds holding IPHA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $2.64B AUM 33.63% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $6.82B AUM 17.15% 1-Year Est. Return